Ｐａｇｅ 831786 ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 通常モードに戻る ┃ ＩＮＤＥＸ ┃ ≪前へ │ 次へ≫ ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ ▼According to the pa unseriere 13/10/3(木) 20:01 ─────────────────────────────────────── ■題名 ： According to the pa ■名前 ： unseriere <Conyinozyoj@allairmaxsaleoutlet.us> ■日付 ： 13/10/3(木) 20:01 ■Ｗｅｂ ： http://www.coach-outlets-discount.com/ -------------------------------------------------------------------------
| Buried within the オロビアンコ バッグ メンズ Dealing that progressively Hollywood sensations are wearing boots from UGG Australia オロビアンコ ボディバッグ ネイビー Dealing that progressively Hollywood sensations are wearing boots from UGG Australia オロビアンコ 長財布 ラウンド Dealing that progressively Hollywood sensations are wearing boots from UGG Australia オロビアンコ ボディバッグ ジャコミーノ Generic Drugs Battlefield Generic pharmaceuticals as an sector has highly favorable demand dynamics. A few secular trends are converging that may advantage オロビアンコ 時計 メンズ this market place. are aggressively looking for out strategies to lessen skyrocketing health care costs. Due to the fact オロビアンコ バッグ メンズ 人気 1960, healthcare spending has expanded from 5% of GDP to over 17% in 2009. Prescription drugs account for about 10% of all healthcare spending, so that is an clear region to target. Generic versions of branded drugs generally sell for half to onethird on the price. Provided this, health care payers have often オロビアンコ バッグ トート limited reimbursement to generic versions of certain remedies, raising the demand for them. From 2004 to 2009, generics marketplace share rose from 56% of prescription dollars to practically http://xn--cckp2a1j7eob1457jm0f.tooth-body.com/ 75%. Among the list of 2010 healthcare bill's major objectives was to increase access for the roughly 15% of Americans with no wellness insurance coverage. By eliminating insurance denials due to existing circumstances, stopping the dropping coverage for sick patients, and offering incentives to compact companies giving coverage, even more consumers might be insured and more persons are going to be http://xn--cckp2a2a8irdud5bc.lwvlosangeles.com/ in a position to purchase prescriptions. Ultimately, there is certainly オロビアンコ 時計 評判 demographics. The number of Americans more than 65 will raise 3% a year over the subsequent ten http://xn--cckp2a1j7eob0556cok1a.tooth-body.com/ years, an additional 14 million individuals entering Medicare. Naturally, older people in general call for significantly more healthcare care, such as prescription drugs. Put it all collectively as well as the picture is bright for generics. This trend is set to accelerate more than the following handful of years. 6 オロビアンコ 長財布 メンズ with the major 20 perfect オロビアンコ ベルト 日本製 promoting branded drugs are set to lose patent protection in 2011 and 2012, with two extra オロビアンコ バッグ メンズ 人気 drugs that have more than a billion dollars a year in sales expiring in 2012. That is an astounding $43 billion dollars in branded drug sales that may be open to generic competition. So it would appear to be a slam dunk to advise generics maker Par Pharmaceuticals (PRX) as an desirable Magic Formula stock. Par generates 90% of its sales from generics, and all of its income. Par includes a two pronged technique. First, it targets smaller and much less competitive drugs to develop. By doing this, the organization can beat its competitors in filing abbreviated new drug applications (ANDAs) together with the FDA, which supplies 180 days of advertising exclusivity immediately after the branded drug goes off patent. This is large in the generics home business windfalls from highmargin sales in these 180 days can usually generate quite a few "normal years" worth of profits. This gives Par a slight competitive benefit and also makes it possible for them to charge a little additional. Around the downside, it frequently requires Par to pay royalties towards the branded maker. Par will not be rather the slam dunk it would appear シップス オロビアンコ レディース to be. The corporation isn't targeting any with the aforementioned blockbuster drugs there's just too much competition http://xn--cckp2a1j7eob5289c317a.tooth-body.com/ for them. And that is certainly one of the major complications with this market. Scale is hugely crucial http://xn--cckp2a1j7eob5289c317a.lwvlosangeles.com/ to generating economical gross margins and keeping the legal talent needed to succeed in patent challenges. At just $1 billion in sales, Par pales in comparison to Teva (TEVA) ($16 billion), Sandoz (NVS) ($9 billion), or Mylan (MYL) ($5.4 billion), to not mention quite a few equivalent sized competitors. After exclusivity periods finish, competitors quite often floods in to the marketplace, driving down sales and margins. A good instance オロビアンコ 時計 ブルー of this can be Par's largest item: a generic version of AstraZeneca's (AZN) Toprol XL (metroprolol). Early on, competition was limited, and after that there was no competition in first two quarters of 2009, driving a 100% sales enhance オロビアンコ 時計 TICTAC over 2008. Then again, Watson (WPI) came in to the industry in late 2009, and due to the fact オロビアンコ 時計 ベルト 交換 then an Indian generics firm has also entered. Pricing and volumes suffered. Inside the justreported initially quarter of 2011, metroprolol sales fell 65% more than the prior year! Competitors also can result in cheating. In Q1, Par recorded a $190 million charge to settle claims with the firm オロビアンコ ボディバッグ レザー overinflating the wholesale prices オロビアンコ バッグ オレンジ they report to insurers. The alleged scheme is that Par (and competitors) charge significantly less to pharmacies and report larger promoting prices to insurers. Considering the fact that the insurer is reimbursing the pharmacy at a higher price than they pay for the drugs, it is a good reason オロビアンコ バッグ ブルーグレー for the pharmacy to opt for Par's product more than a competitor's. This is a difficult business to value. It really is hard to predict the impact of new competitors on existing sales, and if Par is going to be capable to win exclusivity. The firm reports 12 firsttofile ANDAs, two prospective firsttomarket opportunities, and strategy five to 7 new ANDA filings a year more than the next couple of years. Revenues and profitability are extremely boomandbust. Par also includes a branded drug unit referred to as Strativa, but so far this unit has been unprofitable, and in all probability will stay so for numerous years. You can find a range of possibilities for Par, but a median case puts a fair value http://xn--cckp2a1j7eob1457jm0f.lwvlosangeles.com/ of about $40 on the stock. Due to the fact this can be a extremely uncertain calculation, MagicDiligence has a neutral opinion. You will discover much better Magic Formula stocks to think about. |